Loading...
XKRX
950130
Market cap221mUSD
Aug 14, Last price  
9,060.00KRW
Name

Access Bio Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.30%
Rev. gr., 5y
21.17%
Revenues
112.46b
-67.74%
36,997,543,00045,840,015,00032,305,084,00035,582,621,00032,485,928,00029,464,754,00040,239,207,00043,058,688,000121,797,380,000505,111,695,0001,033,863,094,000348,643,147,000112,462,797,000
Net income
-348m
L-89.05%
7,451,130,0007,838,027,0002,432,290,0001,265,161,000304,159,000-6,485,782,000-4,240,612,000-20,656,016,00048,272,499,000189,689,851,000346,670,216,000-3,172,838,000-347,576,000
CFO
19.90b
P
1,845,660,0001,587,126,000-2,748,909,0002,865,213,0002,553,507,000-5,445,311,000-5,730,652,000-422,239,00036,722,089,000163,476,864,000369,197,603,000-103,882,450,00019,904,217,000
Dividend
Dec 28, 2022871 KRW/sh

Profile

Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.
URL
https://accessbio.net/
IPO date
May 30, 2013
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
112,462,797
-67.74%
348,643,147
-66.28%
1,033,863,094
104.68%
Cost of revenue
94,323,867
365,100,730
538,820,074
Unusual Expense (Income)
NOPBT
18,138,930
(16,457,583)
495,043,020
NOPBT Margin
16.13%
47.88%
Operating Taxes
936,004
(580,477)
113,950,620
Tax Rate
5.16%
23.02%
NOPAT
17,202,926
(15,877,106)
381,092,400
Net income
(347,576)
-89.05%
(3,172,838)
-100.92%
346,670,216
82.76%
Dividends
(29,341,410)
Dividend yield
Proceeds from repurchase of equity
(1,959,192)
(28,048,211)
BB yield
6.11%
Debt
Debt current
20,094,255
13,426,642
12,979,119
Long-term debt
97,215,381
109,082,792
114,049,447
Deferred revenue
635,799
Other long-term liabilities
Net debt
(294,758,149)
(260,767,745)
(355,893,600)
Cash flow
Cash from operating activities
19,904,217
(103,882,450)
369,197,603
CAPEX
(2,051,110)
(18,672,723)
(18,908,106)
Cash from investing activities
17,468,732
(46,490,664)
(37,754,066)
Cash from financing activities
(7,555,740)
(53,989,107)
(67,413,860)
FCF
34,805,290
(31,997,246)
345,107,460
Balance
Cash
454,846,959
346,976,330
498,714,243
Long term investments
(42,779,174)
36,300,849
(15,792,077)
Excess cash
406,444,645
365,845,022
431,229,011
Stockholders' equity
652,187,927
573,312,418
600,452,592
Invested Capital
309,707,288
291,451,212
262,278,375
ROIC
5.72%
177.41%
ROCE
2.52%
71.38%
EV
Common stock shares outstanding
35,122
34,866
37,632
Price
12,200.00
-23.75%
Market cap
459,116,000
-22.44%
EV
111,208,302
EBITDA
38,216,669
(497,741)
505,869,516
EV/EBITDA
0.22
Interest
3,470,016
3,710,714
6,233,160
Interest/NOPBT
19.13%
1.26%